The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.
We describe five patients with HIV-2 infection (four antiretroviral-experienced and one antiretroviral-naive) treated with a regimen containing raltegravir. All responded to treatment as demonstrated by viral load and CD4(+) T-cell count monitoring. Our series confirms the clinical effectiveness of raltegravir in HIV-2-infected patients when given with other antiretrovirals to which the virus is susceptible.
Department of Clinical Science, Institute of Tropical Medicine, Antwerp, Belgium. kpeterson@itg.be
Kevin
K
Peterson
Jean
J
Ruelle
Marc
M
Vekemans
Frederick P
FP
Siegal
Jane R
JR
Deayton
Robert
R
Colebunders
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015224:Dideoxynucleosides / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015498:HIV-2 / Q000472:pathogenicity*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011760:Pyrrolidinones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D019562:Viral Load; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000099227:Abacavir